Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin

被引:73
作者
Miller, CD
Lomaestro, BW
Park, S
Perlin, DS
机构
[1] Albany Coll Pharm, Dept Pharm Practice, Albany, NY 12208 USA
[2] Albany Med Coll, Div HIV Med, Albany, NY 12208 USA
[3] Albany Med Ctr Hosp, Dept Pharm, Albany, NY 12208 USA
[4] Publ Res Inst, Newark, NJ USA
来源
PHARMACOTHERAPY | 2006年 / 26卷 / 06期
关键词
caspofungin; Candida albicans; resistance; esophagitis; human immunodeficiency virus; HIV; susceptibility;
D O I
10.1592/phco.26.6.877
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Candida esophagitis, a defining illness of acquired immunodeficiency syndrome (AIDS), requires systemic antifungal therapy. Candida albicans can become resistant to commonly administered azole antifungal agents. An attractive alternative is caspofungin, an echinocandin antifungal that has generally displayed predictable activity against C. albicans. We report the case of a 29-year-old woman with AIDS who developed recurrent esophagitis caused by a strain of C. albicans that showed reduced susceptibility to caspofungin (elevated minimum inhibitory concentration of 8 mg/L). Analysis of the strain revealed that it contained a serine-to-proline substitution at position 645 in the FKS1 gene. Clinicians who prescribe caspofungin to treat esophagitis caused by C. albicans should recognize the potential risk, albeit slight, for acquired resistance to caspofungin and possibly other echinocandin antifungal agents in the face of persistent disease. In patients who are refractory or unresponsive to caspofungin therapy, susceptibility testing and/or alternative therapy should be considered.
引用
收藏
页码:877 / 880
页数:4
相关论文
共 12 条
[1]   Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases [J].
Arathoon, EG ;
Gotuzzo, E ;
Noriega, LM ;
Berman, RS ;
DiNubile, MJ ;
Sable, CA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :451-457
[2]   In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].
Bartizal, K ;
Gill, CJ ;
Abruzzo, GK ;
Flattery, AM ;
Kong, L ;
Scott, PM ;
Smith, JG ;
Leighton, CE ;
Bouffard, A ;
Dropinski, JF ;
Balkovec, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332
[3]   In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents:: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003 [J].
Cuenca-Estrella, M ;
Rodriguez, D ;
Almirante, B ;
Morgan, J ;
Planes, AM ;
Almela, M ;
Mensa, J ;
Sanchez, F ;
Ayats, J ;
Gimenez, M ;
Salvado, M ;
Warnock, DW ;
Pahissa, A ;
Rodriguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (02) :194-199
[4]   Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors [J].
Douglas, CM ;
DIppolito, JA ;
Shei, GJ ;
Meinz, M ;
Onishi, J ;
Marrinan, JA ;
Li, W ;
Abruzzo, GK ;
Flattery, A ;
Bartizal, K ;
Mitchell, A ;
Kurtz, MB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2471-2479
[5]   Caspofungin resistance in Candida albicans:: Correlating clinical outcome with laboratory susceptibility testing of three is genic isolates serially obtained from a patient with progressive candida esophagitis [J].
Hernandez, S ;
López-Ribot, JL ;
Najvar, LK ;
McCarthy, DI ;
Bocanegra, R ;
Graybill, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1382-1383
[6]   Characterization of echinocardin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies [J].
Kurtz, MB ;
Abruzzo, G ;
Bartizal, K ;
Marrinan, JA ;
Li, W ;
Milligan, J ;
Nollstadt, K ;
Douglas, CM .
INFECTION AND IMMUNITY, 1996, 64 (08) :3244-3251
[7]  
National Committee for Clinical Laboratory Standards, 2002, M27A2 NCCLS
[8]   Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans [J].
Paderu, P ;
Park, S ;
Perlin, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :3845-3849
[9]   Guidelines for treatment of candidiasis [J].
Pappas, PG ;
Rex, JH ;
Sobel, JD ;
Filler, SG ;
Dismukes, WE ;
Walsh, TJ ;
Edwards, JE .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :161-189
[10]   Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp isolates [J].
Park, S ;
Kelly, R ;
Kahn, JN ;
Robles, J ;
Hsu, MJ ;
Register, E ;
Li, W ;
Vyas, V ;
Fan, H ;
Abruzzo, G ;
Flattery, A ;
Gill, C ;
Chrebet, G ;
Parent, SA ;
Kurtz, A ;
Teppler, H ;
Douglas, CA ;
Perlin, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3264-3273